These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 16906230)

  • 1. EVALUATION OF DRUG ABUSE TREATMENT MEDICATIONS: CONCORDANCE BETWEEN CLINICAL AND PRECLINICAL STUDIES.
    Mello NK
    NIDA Res Monogr; 2005 May; 185():82-104. PubMed ID: 16906230
    [No Abstract]   [Full Text] [Related]  

  • 2. Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures.
    Mello NK; Negus SS
    Neuropsychopharmacology; 1996 Jun; 14(6):375-424. PubMed ID: 8726752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Preclinical Drug vs. Food Choice Procedures to Evaluate Candidate Medications for Cocaine Addiction.
    Banks ML; Hutsell BA; Schwienteck KL; Negus SS
    Curr Treat Options Psychiatry; 2015 Jun; 2(2):136-150. PubMed ID: 26009706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the "Pipeline" for Development of Medications for Cocaine Use Disorder: A Review of Translational Preclinical, Human Laboratory, and Clinical Trial Research.
    Czoty PW; Stoops WW; Rush CR
    Pharmacol Rev; 2016 Jul; 68(3):533-62. PubMed ID: 27255266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of preclinical drug versus food choice procedures to evaluate candidate medications for methamphetamine use disorder.
    Banks ML
    Ann N Y Acad Sci; 2017 Apr; 1394(1):92-105. PubMed ID: 27936284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug abuse potential evaluation in animals.
    Balster RL
    Br J Addict; 1991 Dec; 86(12):1549-58. PubMed ID: 1786486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abuse liability assessment in preclinical drug development: predictivity of a translational approach for abuse liability testing using methylphenidate in four standardized preclinical study models.
    Teuns GB; Geys HM; Geuens SM; Stinissen P; Meert TF
    J Pharmacol Toxicol Methods; 2014; 70(3):295-309. PubMed ID: 24632211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agonist-like pharmacotherapy for stimulant dependence: preclinical, human laboratory, and clinical studies.
    Herin DV; Rush CR; Grabowski J
    Ann N Y Acad Sci; 2010 Feb; 1187():76-100. PubMed ID: 20201847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Environmental influence on the preclinical evaluation of substance use disorder therapeutics.
    Banks ML
    Adv Pharmacol; 2022; 93():219-242. PubMed ID: 35341567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prairie Voles as a Model to Screen Medications for the Treatment of Alcoholism and Addictions.
    Ryabinin AE; Hostetler CM
    Int Rev Neurobiol; 2016; 126():403-21. PubMed ID: 27055620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of human drug self-administration procedures in the development of medications.
    Comer SD; Ashworth JB; Foltin RW; Johanson CE; Zacny JP; Walsh SL
    Drug Alcohol Depend; 2008 Jul; 96(1-2):1-15. PubMed ID: 18436394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling risk factors for nicotine and other drug abuse in the preclinical laboratory.
    Carroll ME; Anker JJ; Perry JL
    Drug Alcohol Depend; 2009 Oct; 104 Suppl 1():S70-8. PubMed ID: 19136222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Research issues related to development of medications for treatment of cocaine addiction.
    Klein M
    Ann N Y Acad Sci; 1998 May; 844():75-91. PubMed ID: 9668666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical Evaluation of Vaccines to Treat Opioid Use Disorders: How Close are We to a Clinically Viable Therapeutic?
    Townsend EA; Banks ML
    CNS Drugs; 2020 May; 34(5):449-461. PubMed ID: 32248427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statistical analysis of preclinical inter-species concordance of histopathological findings in the eTOX database.
    Wright PSR; Briggs KA; Thomas R; Smith GF; Maglennon G; Mikulskis P; Chapman M; Greene N; Phillips BU; Bender A
    Regul Toxicol Pharmacol; 2023 Feb; 138():105308. PubMed ID: 36481279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concordance of Parent- and Child-Reported Physical Abuse Following Child Protective Services Investigation.
    Kobulsky JM; Kepple NJ; Holmes MR; Hussey DL
    Child Maltreat; 2017 Feb; 22(1):24-33. PubMed ID: 27742847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical assessment of abuse liability of drugs.
    Katz JL; Goldberg SR
    Agents Actions; 1988 Feb; 23(1-2):18-26. PubMed ID: 3281421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What factors influence concordance with medications? Findings from the U.K. Asian Diabetes study.
    Lloyd CE; Mughal S; Roy T; Raymond NT; O'Hare JP; Barnett AH; Bellary S
    Diabet Med; 2014 Dec; 31(12):1600-9. PubMed ID: 25073479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medication assisted treatment of drug abuse and dependence: global availability and utilization.
    Kresina TF
    Recent Pat Antiinfect Drug Discov; 2007 Jan; 2(1):79-86. PubMed ID: 18221165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medications in the treatment of addictive disease.
    Wesson DR; Ling W
    J Psychoactive Drugs; 1991; 23(4):365-70. PubMed ID: 1813609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.